{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:08:01Z","timestamp":1788606481890,"version":"build-2803163510"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014941","name":"Cytokinetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20220680"],"award-info":[{"award-number":["20220680"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018696","name":"HORIZON EUROPE Health","doi-asserted-by":"publisher","award":["101095479 - More-EUROPA"],"award-info":[{"award-number":["101095479 - More-EUROPA"]}],"id":[{"id":"10.13039\/100018696","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>We assessed eligibility for omecamtiv mecarbil (OM) in a real-world cohort with heart failure with reduced ejection fraction (HFrEF) according to the selection criteria of the GALACTIC-HF trial (trial scenario) and selected trial\u00b4s criteria more likely to impact real-world use (pragmatic scenario).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We included 31,015 patients with HFrEF lasting \u22653 months and registered in the Swedish HF registry between 2000\u20132021. Trial eligibility was calculated by applying all the GALACTIC-HF selection criteria. The pragmatic scenario considered only the New York Heart Association class, history of worsening HF, N-terminal pro-B-type natriuretic peptides (NT-proBNP), blood pressure and renal failure criteria defined as in the trial. Eligibility for OM in chronic HFrEF was 21% and 36% in the trial and pragmatic scenarios, respectively. Eligibility was higher in those with EF&lt;30% (trial: 27%, pragmatic: 44%), in-patients (trial:30%, pragmatic:57%), severe HF (trial: 35%, pragmatic: 60%), NYHA class III-IV (trial: 26%, pragmatic: 45%), and NT-proBNP\u22655,000pg\/mL (trial: 30%, pragmatic: 51%). The criteria that most limited eligibility were history of a recent worsening HF event (60% eligible in chronic HFrEF), elevated NT-proBNP (82% eligible), and deviating blood pressure (82% eligible). Overall, eligible patients were characterized by more severe HF and higher CV event-rates in both scenarios, and higher comorbidity burden in the pragmatic scenario.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Approximately 21% of real-world chronic HFrEF patients would be eligible for OM according to the GALACTIC-HF selection criteria, and 36% according to the criteria more likely to affect OM use in clinical practice. Criteria in both scenarios identified a patient-group with severe HF and high CV event-rates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0303348","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T13:39:31Z","timestamp":1716557971000},"page":"e0303348","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Eligibility for omecamtiv mecarbil in a real-world heart failure population: Data from the Swedish Heart Failure Registry"],"prefix":"10.1371","volume":"19","author":[{"given":"Felix","family":"Lindberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natanael","family":"\u00d8igaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe M. C.","family":"Rosano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Dahlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Hage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7732-0887","authenticated-orcid":true,"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"issue":"1","key":"pone.0303348.ref001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global Public Health Burden of Heart Failure.","volume":"3","author":"G Savarese","year":"2017","journal-title":"Card Fail Rev"},{"key":"pone.0303348.ref002","article-title":"Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction","author":"SJ Greene","year":"2021","journal-title":"Heart Fail Rev"},{"issue":"9","key":"pone.0303348.ref003","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry.","volume":"20","author":"G Savarese","year":"2018","journal-title":"Eur J Heart Fail."},{"issue":"11","key":"pone.0303348.ref004","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ejhf.1236","article-title":"Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"MG Crespo-Leiro","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"pone.0303348.ref005","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/11585480-000000000-00000","article-title":"Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents","volume":"71","author":"M Metra","year":"2011","journal-title":"Drugs"},{"issue":"3","key":"pone.0303348.ref006","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/ehf2.13859","article-title":"Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care.","volume":"9","author":"D Tomasoni","year":"2022","journal-title":"ESC Heart Fail."},{"issue":"4","key":"pone.0303348.ref007","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ejhf.2814","article-title":"Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology","volume":"25","author":"F Gustafsson","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"pone.0303348.ref008","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.jacc.2019.02.051","article-title":"Cardiac Calcitropes, Myotropes, and Mitotropes: JACC Review Topic of the Week","volume":"73","author":"MA Psotka","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"pone.0303348.ref009","first-page":"e12419","article-title":"Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management.","volume":"13","author":"PH Patel","year":"2021","journal-title":"Cureus"},{"issue":"2","key":"pone.0303348.ref010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure","volume":"384","author":"JR Teerlink","year":"2021","journal-title":"N Engl J Med"},{"issue":"44","key":"pone.0303348.ref011","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1093\/eurheartj\/ehy600","article-title":"Treatments targeting inotropy","volume":"40","author":"C Maack","year":"2019","journal-title":"Eur Heart J"},{"issue":"11","key":"pone.0303348.ref012","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/ejhf.2274","article-title":"Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials","volume":"23","author":"B Schrage","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"pone.0303348.ref013","article-title":"Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: Data from the swedish heart failure registry","author":"PM Becher","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"3","key":"pone.0303348.ref014","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.13165","article-title":"Eligibility for sacubitril\/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry","volume":"289","author":"G Savarese","year":"2021","journal-title":"J Intern Med"},{"issue":"1","key":"pone.0303348.ref015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/03009734.2018.1490831","article-title":"The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure","volume":"124","author":"G Savarese","year":"2019","journal-title":"Ups J Med Sci"},{"key":"pone.0303348.ref016","author":"P. Vasko","journal-title":"SWEDEHEART Annual Report 2022 SwedeHF Appendix"},{"issue":"48","key":"pone.0303348.ref017","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1093\/eurheartj\/ehac293","article-title":"Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial","volume":"43","author":"M Metra","year":"2022","journal-title":"Eur Heart J"},{"issue":"23","key":"pone.0303348.ref018","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1093\/eurheartj\/ehac144","article-title":"Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial","volume":"43","author":"SD Solomon","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"pone.0303348.ref019","first-page":"1","article-title":"mice: Multivariate Imputation by Chained Equations in R.","volume":"45","author":"S van Buuren","year":"2011","journal-title":"J Stat Softw."},{"issue":"7","key":"pone.0303348.ref020","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.cardfail.2022.04.011","article-title":"Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.","volume":"28","author":"T Thorvaldsen","year":"2022","journal-title":"J Card Fail"},{"issue":"9","key":"pone.0303348.ref021","article-title":"Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.","volume":"10","author":"D Das","year":"2017","journal-title":"Circ Heart Fail."},{"key":"pone.0303348.ref022","article-title":"Eligibility for vericiguat in a real-world heart failure population according to trial, guideline and label criteria: Data from the Swedish Heart Failure Registry.","author":"NV Nguyen","year":"2023","journal-title":"Eur J Heart Fail."},{"issue":"4","key":"pone.0303348.ref023","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrcardio.2015.14","article-title":"The vulnerable phase after hospitalization for heart failure","volume":"12","author":"SJ Greene","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"pone.0303348.ref024","doi-asserted-by":"crossref","first-page":"e023766","DOI":"10.1161\/JAHA.121.023766","article-title":"Representativeness of the GALACTIC-HF Clinical Trial in Patients Having Heart Failure With Reduced Ejection Fraction.","volume":"11","author":"MT Mefford","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"pone.0303348.ref025","article-title":"Patient Eligibility for Established and Novel Guideline-Directed Medical Therapies After Acute Heart Failure Hospitalization.","author":"N Moghaddam","year":"2023","journal-title":"JACC Heart Fail"},{"key":"pone.0303348.ref026","article-title":"Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata","author":"D Stolfo","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"pone.0303348.ref027","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40262-021-01014-0","article-title":"Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil.","volume":"60","author":"A Trivedi","year":"2021","journal-title":"Clin Pharmacokinet."},{"issue":"11","key":"pone.0303348.ref028","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/ejhf.2015","article-title":"Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials","volume":"22","author":"JR Teerlink","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"pone.0303348.ref029","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00392-023-02172-w","article-title":"KCCQ total symptom score, clinical outcome measures, and adverse events associated with omecamtiv mecarbil for heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials","volume":"112","author":"R Ibrahim","year":"2023","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"pone.0303348.ref030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jacc.2021.04.065","article-title":"Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF","volume":"78","author":"JR Teerlink","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"pone.0303348.ref031","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/jamacardio.2021.4027","article-title":"Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial.","volume":"7","author":"GM Felker","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"7","key":"pone.0303348.ref032","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/ehjqcco\/qcab070","article-title":"Generalizability of randomized controlled trials in heart failure with reduced ejection fraction","volume":"8","author":"YMF Lim","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"9","key":"pone.0303348.ref033","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/ejhf.762","article-title":"Association between enrolment in a heart failure quality registry and subsequent mortality-a nationwide cohort study","volume":"19","author":"LH Lund","year":"2017","journal-title":"Eur J Heart Fail"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0303348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T13:39:56Z","timestamp":1716557996000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0303348"}},"subtitle":[],"editor":[{"given":"Satoshi","family":"Higuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0303348","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]}}}